$ICPT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in INTERCEPT PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in INTERCEPT PHARMACEUTICALS, INC.. Get notifications about new insider transactions in INTERCEPT PHARMACEUTICALS, INC. for free.
Page: < prev 1 2 3 4 5 6 7 8 ... 13 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 09 2018 | ICPT | INTERCEPT PHARMACE ... | BRADBURY DANIEL | Director | Buy | P | 64.00 | 7,812 | 499,968 | 11,642 | 3.8 K to 11.6 K (+203.97 %) |
Apr 09 2018 | ICPT | INTERCEPT PHARMACE ... | Genextra S.p.A. | Buy | P | 64.00 | 390,625 | 25,000,000 | 6,845,578 | 6.5 M to 6.8 M (+6.05 %) | |
Apr 09 2018 | ICPT | INTERCEPT PHARMACE ... | Micheli Francesco | Buy | P | 64.00 | 390,625 | 25,000,000 | 6,845,578 | 6.5 M to 6.8 M (+6.05 %) | |
Apr 09 2018 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Grant | A | 64.00 | 234,375 | 15,000,000 | 234,375 | 0 to 234.4 K |
Feb 22 2018 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Option Exercise | A | 58.74 | 8,300 | 487,542 | 8,300 | |
Feb 22 2018 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Grant | A | 0.00 | 5,500 | 0 | 30,385 | 24.9 K to 30.4 K (+22.10 %) |
Feb 22 2018 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Option Exercise | A | 58.74 | 6,600 | 387,684 | 6,600 | |
Feb 22 2018 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Grant | A | 0.00 | 4,300 | 0 | 10,300 | 6 K to 10.3 K (+71.67 %) |
Feb 22 2018 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | A | 58.74 | 45,500 | 2,672,670 | 45,500 | |
Feb 22 2018 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP Research and De ... | Option Exercise | A | 58.74 | 3,200 | 187,968 | 3,200 | |
Feb 22 2018 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP Research and De ... | Grant | A | 0.00 | 2,100 | 0 | 18,600 | 16.5 K to 18.6 K (+12.73 %) |
Feb 22 2018 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | Chief Operating Off ... | Option Exercise | A | 58.74 | 20,700 | 1,215,918 | 20,700 | |
Feb 22 2018 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | Chief Operating Off ... | Grant | A | 0.00 | 13,600 | 0 | 28,600 | 15 K to 28.6 K (+90.67 %) |
Feb 22 2018 | ICPT | INTERCEPT PHARMACE ... | Kim Richard J | President U.S. Comm ... | Option Exercise | A | 58.74 | 8,800 | 516,912 | 8,800 | |
Feb 22 2018 | ICPT | INTERCEPT PHARMACE ... | Kim Richard J | President U.S. Comm ... | Grant | A | 0.00 | 5,800 | 0 | 17,005 | 11.2 K to 17 K (+51.76 %) |
Feb 22 2018 | ICPT | INTERCEPT PHARMACE ... | Kapadia Sandip | Chief Financial Off ... | Option Exercise | A | 58.74 | 10,500 | 616,770 | 10,500 | |
Feb 22 2018 | ICPT | INTERCEPT PHARMACE ... | Kapadia Sandip | Chief Financial Off ... | Grant | A | 0.00 | 6,900 | 0 | 27,115 | 20.2 K to 27.1 K (+34.13 %) |
Feb 22 2018 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | Chief Medical Offic ... | Option Exercise | A | 58.74 | 4,400 | 258,456 | 4,400 | |
Feb 22 2018 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | Chief Medical Offic ... | Grant | A | 0.00 | 2,900 | 0 | 47,113 | 44.2 K to 47.1 K (+6.56 %) |
Feb 15 2018 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel | Option Exercise | A | 53.41 | 35,300 | 1,885,373 | 35,300 | |
Feb 15 2018 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel | Grant | A | 0.00 | 23,200 | 0 | 23,200 | 0 to 23.2 K |
Jan 26 2018 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Grant | A | 0.00 | 879 | 0 | 24,885 | 24 K to 24.9 K (+3.66 %) |
Jan 26 2018 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Grant | A | 0.00 | 879 | 0 | 24,006 | 23.1 K to 24 K (+3.80 %) |
Jan 26 2018 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Grant | A | 0.00 | 293 | 0 | 23,127 | 22.8 K to 23.1 K (+1.28 %) |
Jan 26 2018 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Grant | A | 0.00 | 879 | 0 | 24,885 | 24 K to 24.9 K (+3.66 %) |
Jan 26 2018 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Grant | A | 0.00 | 879 | 0 | 24,006 | 23.1 K to 24 K (+3.80 %) |
Jan 26 2018 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Grant | A | 0.00 | 293 | 0 | 23,127 | 22.8 K to 23.1 K (+1.28 %) |
Dec 11 2017 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP Research and De ... | Option Exercise | A | 59.12 | 25,000 | 1,478,000 | 25,000 | |
Dec 11 2017 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP Research and De ... | Grant | A | 0.00 | 16,500 | 0 | 16,500 | 0 to 16.5 K |
Oct 04 2017 | ICPT | INTERCEPT PHARMACE ... | Kim Richard J | SVP, Commercial US | Sell | S | 58.10 | 48 | 2,789 | 11,205 | 11.3 K to 11.2 K (-0.43 %) |
Oct 04 2017 | ICPT | INTERCEPT PHARMACE ... | Kapadia Sandip | Chief Financial Off ... | Sell | S | 58.83 | 354 | 20,827 | 20,215 | 20.6 K to 20.2 K (-1.72 %) |
Oct 04 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Sell | S | 58.92 | 390 | 22,980 | 22,834 | 23.2 K to 22.8 K (-1.68 %) |
Oct 04 2017 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 58.90 | 349 | 20,556 | 44,213 | 44.6 K to 44.2 K (-0.78 %) |
Oct 04 2017 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 58.87 | 1,532 | 90,189 | 568,752 | 570.3 K to 568.8 K (-0.27 %) |
Oct 04 2017 | ICPT | INTERCEPT PHARMACE ... | McMinn Rachel | Chief Strategy Offi ... | Sell | S | 58.89 | 283 | 16,667 | 16,875 | 17.2 K to 16.9 K (-1.65 %) |
Sep 05 2017 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 31.90 | 1,250 | 39,875 | 21,031 | |
Sep 05 2017 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 117.43 | 1,250 | 146,788 | 44,562 | 45.8 K to 44.6 K (-2.73 %) |
Sep 05 2017 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 31.90 | 1,250 | 39,875 | 45,812 | 44.6 K to 45.8 K (+2.81 %) |
Aug 29 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Sell | S | 111.35 | 100 | 11,135 | 23,224 | 23.3 K to 23.2 K (-0.43 %) |
Aug 29 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Sell | S | 111.28 | 153 | 17,026 | 23,324 | 23.5 K to 23.3 K (-0.65 %) |
Aug 02 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Sell | S | 110.29 | 142 | 15,661 | 23,477 | 23.6 K to 23.5 K (-0.60 %) |
Aug 02 2017 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 8.67 | 1,118 | 9,689 | 0 | |
Aug 02 2017 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 119.00 | 1,118 | 133,042 | 44,562 | 45.7 K to 44.6 K (-2.45 %) |
Aug 02 2017 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 8.67 | 1,118 | 9,689 | 45,680 | 44.6 K to 45.7 K (+2.51 %) |
Aug 02 2017 | ICPT | INTERCEPT PHARMACE ... | WELCH DANIEL G | Director | Sell | S | 123.93 | 602 | 74,604 | 3,108 | 3.7 K to 3.1 K (-16.23 %) |
Aug 02 2017 | ICPT | INTERCEPT PHARMACE ... | McMinn Rachel | Chief Strategy Offi ... | Sell | S | 123.12 | 130 | 16,005 | 17,158 | 17.3 K to 17.2 K (-0.75 %) |
Jul 21 2017 | ICPT | INTERCEPT PHARMACE ... | WELCH DANIEL G | Director | Sell | S | 126.76 | 217 | 27,507 | 3,710 | 3.9 K to 3.7 K (-5.53 %) |
Jul 18 2017 | ICPT | INTERCEPT PHARMACE ... | Kim Richard J | SVP, Commercial US | Sell | S | 128.64 | 89 | 11,449 | 11,253 | 11.3 K to 11.3 K (-0.78 %) |
Jul 13 2017 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 124.01 | 553 | 68,578 | 44,562 | 45.1 K to 44.6 K (-1.23 %) |
Jul 05 2017 | ICPT | INTERCEPT PHARMACE ... | Kapadia Sandip | Chief Financial Off ... | Sell | S | 121.59 | 1,431 | 173,999 | 20,569 | 22 K to 20.6 K (-6.50 %) |
Jul 05 2017 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 121.35 | 100 | 12,135 | 45,115 | 45.2 K to 45.1 K (-0.22 %) |
Jul 05 2017 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 121.20 | 250 | 30,300 | 45,215 | 45.5 K to 45.2 K (-0.55 %) |
Jul 05 2017 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 121.78 | 1,434 | 174,633 | 570,284 | 571.7 K to 570.3 K (-0.25 %) |
Jul 05 2017 | ICPT | INTERCEPT PHARMACE ... | McMinn Rachel | Chief Strategy Offi ... | Sell | S | 121.78 | 257 | 31,297 | 17,288 | 17.5 K to 17.3 K (-1.46 %) |
Jul 05 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Sell | S | 121.33 | 394 | 47,802 | 23,619 | 24 K to 23.6 K (-1.64 %) |
Jul 05 2017 | ICPT | INTERCEPT PHARMACE ... | Kim Richard J | SVP, Commercial US | Sell | S | 121.69 | 50 | 6,085 | 11,342 | 11.4 K to 11.3 K (-0.44 %) |
Jun 29 2017 | ICPT | INTERCEPT PHARMACE ... | SBLENDORIO GLENN | Director | Option Exercise | A | 122.01 | 2,036 | 248,412 | 2,036 | |
Jun 29 2017 | ICPT | INTERCEPT PHARMACE ... | SBLENDORIO GLENN | Director | Grant | A | 0.00 | 1,423 | 0 | 3,729 | 2.3 K to 3.7 K (+61.71 %) |
Jun 29 2017 | ICPT | INTERCEPT PHARMACE ... | SANTINI GINO | Director | Option Exercise | A | 122.01 | 2,036 | 248,412 | 2,036 | |
Jun 29 2017 | ICPT | INTERCEPT PHARMACE ... | SANTINI GINO | Director | Grant | A | 0.00 | 1,423 | 0 | 3,927 | 2.5 K to 3.9 K (+56.83 %) |
Jun 29 2017 | ICPT | INTERCEPT PHARMACE ... | WELCH DANIEL G | Director | Option Exercise | A | 122.01 | 2,036 | 248,412 | 2,036 | |
Jun 29 2017 | ICPT | INTERCEPT PHARMACE ... | WELCH DANIEL G | Director | Grant | A | 0.00 | 1,423 | 0 | 3,927 | 2.5 K to 3.9 K (+56.83 %) |
Jun 29 2017 | ICPT | INTERCEPT PHARMACE ... | BRADBURY DANIEL | Director | Option Exercise | A | 122.01 | 2,036 | 248,412 | 2,036 | |
Jun 29 2017 | ICPT | INTERCEPT PHARMACE ... | BRADBURY DANIEL | Director | Grant | A | 0.00 | 1,423 | 0 | 3,830 | 2.4 K to 3.8 K (+59.12 %) |
Jun 29 2017 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Option Exercise | A | 122.01 | 2,036 | 248,412 | 2,036 | |
Jun 29 2017 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Grant | A | 0.00 | 1,423 | 0 | 14,669 | 13.2 K to 14.7 K (+10.74 %) |
Jun 29 2017 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Option Exercise | A | 122.01 | 2,036 | 248,412 | 2,036 | |
Jun 29 2017 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Grant | A | 0.00 | 1,423 | 0 | 11,498 | 10.1 K to 11.5 K (+14.12 %) |
Jun 29 2017 | ICPT | INTERCEPT PHARMACE ... | Benatti Luca | Director | Option Exercise | A | 122.01 | 2,036 | 248,412 | 2,036 | |
Jun 29 2017 | ICPT | INTERCEPT PHARMACE ... | Benatti Luca | Director | Grant | A | 0.00 | 1,423 | 0 | 4,569 | 3.1 K to 4.6 K (+45.23 %) |
Jun 29 2017 | ICPT | INTERCEPT PHARMACE ... | Gottesdiener Keith Michael | Director | Option Exercise | A | 122.01 | 2,036 | 248,412 | 2,036 | |
Jun 29 2017 | ICPT | INTERCEPT PHARMACE ... | Gottesdiener Keith Michael | Director | Grant | A | 0.00 | 1,423 | 0 | 3,830 | 2.4 K to 3.8 K (+59.12 %) |
Jun 28 2017 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 40,000 | 346,668 | 50,039 | |
Jun 28 2017 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 133.08 | 2,043 | 271,872 | 571,718 | 573.8 K to 571.7 K (-0.36 %) |
Jun 28 2017 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 132.54 | 5,485 | 726,996 | 573,761 | 579.2 K to 573.8 K (-0.95 %) |
Jun 28 2017 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 131.18 | 5,893 | 773,050 | 579,246 | 585.1 K to 579.2 K (-1.01 %) |
Jun 28 2017 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 130.46 | 18,763 | 2,447,845 | 585,139 | 603.9 K to 585.1 K (-3.11 %) |
Jun 28 2017 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 129.49 | 7,816 | 1,012,101 | 603,902 | 611.7 K to 603.9 K (-1.28 %) |
Jun 28 2017 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 40,000 | 346,668 | 611,718 | 571.7 K to 611.7 K (+7.00 %) |
Jun 02 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Sell | S | 110.85 | 150 | 16,628 | 24,013 | 24.2 K to 24 K (-0.62 %) |
Jun 02 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Sell | S | 110.70 | 450 | 49,815 | 24,163 | 24.6 K to 24.2 K (-1.83 %) |
Jun 02 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Sell | S | 110.68 | 98 | 10,846 | 24,613 | 24.7 K to 24.6 K (-0.40 %) |
Jun 02 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Grant | A | 0.00 | 1,465 | 0 | 24,711 | 23.2 K to 24.7 K (+6.30 %) |
May 30 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Sell | S | 117.52 | 254 | 29,850 | 23,246 | 23.5 K to 23.2 K (-1.08 %) |
May 18 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Sell | S | 119.77 | 100 | 11,977 | 23,500 | 23.6 K to 23.5 K (-0.42 %) |
May 18 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Sell | S | 119.56 | 13 | 1,554 | 23,600 | 23.6 K to 23.6 K (-0.06 %) |
May 18 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Grant | A | 0.00 | 235 | 0 | 23,613 | 23.4 K to 23.6 K (+1.01 %) |
May 10 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Sell | S | 114.00 | 426 | 48,564 | 23,378 | 23.8 K to 23.4 K (-1.79 %) |
May 10 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Grant | A | 0.00 | 879 | 0 | 23,804 | 22.9 K to 23.8 K (+3.83 %) |
May 10 2017 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Option Exercise | A | 114.90 | 12,000 | 1,378,800 | 12,000 | |
May 10 2017 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Grant | A | 0.00 | 6,000 | 0 | 6,000 | 0 to 6 K |
May 03 2017 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 8.67 | 1,117 | 9,681 | 1,118 | |
May 03 2017 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 112.18 | 1,117 | 125,305 | 45,465 | 46.6 K to 45.5 K (-2.40 %) |
May 03 2017 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 8.67 | 1,117 | 9,681 | 46,582 | 45.5 K to 46.6 K (+2.46 %) |
May 03 2017 | ICPT | INTERCEPT PHARMACE ... | McMinn Rachel | Chief Strategy Offi ... | Sell | S | 113.12 | 114 | 12,896 | 17,545 | 17.7 K to 17.5 K (-0.65 %) |
Apr 11 2017 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 108.51 | 558 | 60,549 | 45,465 | 46 K to 45.5 K (-1.21 %) |
Apr 05 2017 | ICPT | INTERCEPT PHARMACE ... | McMinn Rachel | Chief Strategy Offi ... | Sell | S | 115.00 | 257 | 29,554 | 17,659 | 17.9 K to 17.7 K (-1.43 %) |
Apr 05 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Sell | S | 115.00 | 389 | 44,734 | 22,925 | 23.3 K to 22.9 K (-1.67 %) |
Apr 05 2017 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 115.00 | 346 | 39,789 | 46,023 | 46.4 K to 46 K (-0.75 %) |
Apr 05 2017 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 115.00 | 1 | 115 | 571,718 | 571.7 K to 571.7 K (0.00 %) |
Mar 06 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Sell | S | 130.16 | 1,313 | 170,903 | 23,314 | 24.6 K to 23.3 K (-5.33 %) |
Mar 06 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Grant | A | 0.00 | 2,814 | 0 | 24,627 | 21.8 K to 24.6 K (+12.90 %) |
Mar 03 2017 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 21.50 | 1,350 | 29,025 | 5,786 | |
Mar 03 2017 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 128.66 | 1,350 | 173,691 | 46,369 | 47.7 K to 46.4 K (-2.83 %) |
Mar 03 2017 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 21.50 | 1,350 | 29,025 | 47,719 | 46.4 K to 47.7 K (+2.91 %) |
Mar 03 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Sell | S | 130.16 | 136 | 17,702 | 21,813 | 21.9 K to 21.8 K (-0.62 %) |
Mar 03 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Grant | A | 0.00 | 293 | 0 | 21,949 | 21.7 K to 21.9 K (+1.35 %) |
Mar 01 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Sell | S | 119.48 | 254 | 30,348 | 21,695 | 21.9 K to 21.7 K (-1.16 %) |
Feb 27 2017 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | Chief Operating Off ... | Option Exercise | A | 115.93 | 20,000 | 2,318,600 | 20,000 | |
Feb 27 2017 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | Chief Operating Off ... | Grant | A | 0.00 | 15,000 | 0 | 15,000 | 0 to 15 K |
Feb 03 2017 | ICPT | INTERCEPT PHARMACE ... | McMinn Rachel | Chief Strategy Offi ... | Option Exercise | A | 107.18 | 8,300 | 889,594 | 8,300 | |
Feb 03 2017 | ICPT | INTERCEPT PHARMACE ... | McMinn Rachel | Chief Strategy Offi ... | Grant | A | 0.00 | 5,000 | 0 | 17,916 | 12.9 K to 17.9 K (+38.71 %) |
Feb 03 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Option Exercise | A | 107.18 | 7,800 | 836,004 | 7,800 | |
Feb 03 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Grant | A | 0.00 | 4,700 | 0 | 21,949 | 17.2 K to 21.9 K (+27.25 %) |
Feb 03 2017 | ICPT | INTERCEPT PHARMACE ... | Kapadia Sandip | Chief Financial Off ... | Option Exercise | A | 107.18 | 11,600 | 1,243,288 | 11,600 | |
Feb 03 2017 | ICPT | INTERCEPT PHARMACE ... | Kapadia Sandip | Chief Financial Off ... | Grant | A | 0.00 | 7,000 | 0 | 22,000 | 15 K to 22 K (+46.67 %) |
Feb 03 2017 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | A | 107.18 | 10,000 | 1,071,800 | 10,000 | |
Feb 03 2017 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Grant | A | 0.00 | 6,000 | 0 | 46,369 | 40.4 K to 46.4 K (+14.86 %) |
Feb 03 2017 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | A | 107.18 | 40,000 | 4,287,200 | 40,000 | |
Feb 03 2017 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Grant | A | 0.00 | 23,200 | 0 | 575,905 | 552.7 K to 575.9 K (+4.20 %) |
Feb 02 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Sell | S | 108.96 | 134 | 14,601 | 17,249 | 17.4 K to 17.2 K (-0.77 %) |
Feb 02 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Grant | A | 0.00 | 293 | 0 | 17,383 | 17.1 K to 17.4 K (+1.71 %) |
Jan 11 2017 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 106.01 | 1,565 | 165,906 | 40,369 | 41.9 K to 40.4 K (-3.73 %) |
Jan 05 2017 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Sell | S | 103.92 | 1,119 | 116,285 | 17,090 | 18.2 K to 17.1 K (-6.15 %) |
Jan 05 2017 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 103.92 | 988 | 102,672 | 41,934 | 42.9 K to 41.9 K (-2.30 %) |
Jan 05 2017 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 103.92 | 2,802 | 291,181 | 552,705 | 555.5 K to 552.7 K (-0.50 %) |
Jan 05 2017 | ICPT | INTERCEPT PHARMACE ... | McMinn Rachel | Chief Strategy Offi ... | Sell | S | 103.92 | 816 | 84,798 | 12,916 | 13.7 K to 12.9 K (-5.94 %) |
Dec 08 2016 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 31.90 | 2,405 | 76,720 | 1,354 | |
Dec 08 2016 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 21.50 | 1,082 | 23,263 | 0 | |
Dec 08 2016 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 31.90 | 2,405 | 76,720 | 555,507 | 553.1 K to 555.5 K (+0.43 %) |
Dec 08 2016 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 21.50 | 1,082 | 23,263 | 553,102 | 552 K to 553.1 K (+0.20 %) |
Dec 06 2016 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 99.75 | 1,350 | 134,663 | 42,922 | 44.3 K to 42.9 K (-3.05 %) |
Nov 29 2016 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Sell | S | 113.60 | 249 | 28,286 | 18,209 | 18.5 K to 18.2 K (-1.35 %) |
Nov 17 2016 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Sell | S | 112.27 | 140 | 15,718 | 18,458 | 18.6 K to 18.5 K (-0.75 %) |
Nov 17 2016 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President Internati ... | Grant | A | 0.00 | 293 | 0 | 18,598 | 18.3 K to 18.6 K (+1.60 %) |
Nov 02 2016 | ICPT | INTERCEPT PHARMACE ... | McMinn Rachel | Chief Strategy Offi ... | Sell | S | 123.82 | 129 | 15,972 | 13,732 | 13.9 K to 13.7 K (-0.93 %) |
Oct 12 2016 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 153.34 | 411 | 63,023 | 44,272 | 44.7 K to 44.3 K (-0.92 %) |
Oct 05 2016 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 163.20 | 705 | 115,056 | 552,020 | 552.7 K to 552 K (-0.13 %) |
Oct 05 2016 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 21.50 | 1,350 | 29,025 | 8,486 | |
Oct 05 2016 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 163.20 | 163 | 26,602 | 44,683 | 44.8 K to 44.7 K (-0.36 %) |
Oct 05 2016 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 163.06 | 1,350 | 220,131 | 44,846 | 46.2 K to 44.8 K (-2.92 %) |
Oct 05 2016 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 21.50 | 1,350 | 29,025 | 46,196 | 44.8 K to 46.2 K (+3.01 %) |
Oct 05 2016 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Accounting Of ... | Sell | S | 163.20 | 147 | 23,990 | 30,661 | 30.8 K to 30.7 K (-0.48 %) |
Oct 05 2016 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | See Remarks | Sell | S | 163.20 | 155 | 25,296 | 18,305 | 18.5 K to 18.3 K (-0.84 %) |
Sep 28 2016 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 166.03 | 886 | 147,103 | 44,846 | 45.7 K to 44.8 K (-1.94 %) |
Sep 28 2016 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 164.76 | 2,659 | 438,097 | 45,732 | 48.4 K to 45.7 K (-5.49 %) |
Sep 22 2016 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 9.88 | 8,411 | 83,120 | 0 | |
Sep 22 2016 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 26,589 | 230,439 | 90,039 | |
Sep 22 2016 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 165.00 | 35,000 | 5,775,000 | 552,725 | 587.7 K to 552.7 K (-5.96 %) |
Sep 22 2016 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 9.82 | 8,411 | 82,615 | 587,725 | 579.3 K to 587.7 K (+1.45 %) |